JPMorgan Chase & Co. Issues Positive Forecast for Cellebrite DI (NASDAQ:CLBT) Stock Price

Cellebrite DI (NASDAQ:CLBT) had its target price increased by JPMorgan Chase & Co. from $20.00 to $23.00 in a research note published on Wednesday morning,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the stock.

CLBT has been the subject of a number of other reports. Wall Street Zen lowered shares of Cellebrite DI from a “buy” rating to a “hold” rating in a report on Saturday, September 13th. Lake Street Capital decreased their price objective on shares of Cellebrite DI from $24.00 to $22.00 and set a “buy” rating on the stock in a research report on Friday, August 15th. Finally, Needham & Company LLC dropped their target price on shares of Cellebrite DI from $24.00 to $18.00 and set a “buy” rating for the company in a report on Thursday, August 14th. Four equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, Cellebrite DI presently has a consensus rating of “Buy” and a consensus price target of $21.75.

Cellebrite DI Price Performance

Shares of CLBT stock opened at $18.46 on Wednesday. The stock has a market capitalization of $4.42 billion, a PE ratio of -24.29, a P/E/G ratio of 3.24 and a beta of 1.28. Cellebrite DI has a 1-year low of $13.10 and a 1-year high of $26.30. The business has a 50-day moving average of $15.65 and a 200 day moving average of $16.94.

Cellebrite DI (NASDAQ:CLBT) last announced its quarterly earnings results on Thursday, August 14th. The company reported $0.12 EPS for the quarter, topping analysts’ consensus estimates of $0.11 by $0.01. The business had revenue of $113.28 million for the quarter, compared to analysts’ expectations of $112.33 million. Cellebrite DI had a positive return on equity of 23.92% and a negative net margin of 34.56%.The business’s quarterly revenue was up 18.4% on a year-over-year basis. During the same period in the previous year, the firm earned $0.10 EPS. Cellebrite DI has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Analysts anticipate that Cellebrite DI will post 0.3 EPS for the current year.

Hedge Funds Weigh In On Cellebrite DI

Hedge funds and other institutional investors have recently modified their holdings of the stock. Signaturefd LLC raised its stake in Cellebrite DI by 68.3% in the second quarter. Signaturefd LLC now owns 2,019 shares of the company’s stock worth $32,000 after buying an additional 819 shares in the last quarter. Assetmark Inc. bought a new position in shares of Cellebrite DI in the 1st quarter worth approximately $33,000. PNC Financial Services Group Inc. raised its position in shares of Cellebrite DI by 1,998.0% in the 2nd quarter. PNC Financial Services Group Inc. now owns 2,098 shares of the company’s stock worth $34,000 after acquiring an additional 1,998 shares in the last quarter. Catalyst Capital Advisors LLC purchased a new position in shares of Cellebrite DI in the 1st quarter valued at approximately $51,000. Finally, Virtus Advisers LLC bought a new stake in shares of Cellebrite DI during the first quarter valued at approximately $63,000. Hedge funds and other institutional investors own 45.88% of the company’s stock.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.